JP2018514199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514199A5 JP2018514199A5 JP2017552966A JP2017552966A JP2018514199A5 JP 2018514199 A5 JP2018514199 A5 JP 2018514199A5 JP 2017552966 A JP2017552966 A JP 2017552966A JP 2017552966 A JP2017552966 A JP 2017552966A JP 2018514199 A5 JP2018514199 A5 JP 2018514199A5
- Authority
- JP
- Japan
- Prior art keywords
- replicable
- transgene
- oncolytic virus
- adenovirus
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000309459 oncolytic virus Species 0.000 claims 15
- 108700019146 Transgenes Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 11
- 241000701161 unidentified adenovirus Species 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108010012236 Chemokines Proteins 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 230000000174 oncolytic effect Effects 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- -1 CCL17 Proteins 0.000 claims 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 2
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091008606 PDGF receptors Proteins 0.000 claims 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 2
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 claims 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 238000004873 anchoring Methods 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950002830 enadenotucirev Drugs 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 101150063421 l5 gene Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018041788A JP6928380B2 (ja) | 2015-04-30 | 2018-03-08 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2021129196A JP7162929B2 (ja) | 2015-04-30 | 2021-08-05 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
| GB1507419.8 | 2015-04-30 | ||
| GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
| GB1516936.0 | 2015-09-24 | ||
| GB1522013.0 | 2015-12-14 | ||
| GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
| PCT/EP2016/059609 WO2016174200A1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041788A Division JP6928380B2 (ja) | 2015-04-30 | 2018-03-08 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2021129196A Division JP7162929B2 (ja) | 2015-04-30 | 2021-08-05 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514199A JP2018514199A (ja) | 2018-06-07 |
| JP2018514199A5 true JP2018514199A5 (cg-RX-API-DMAC7.html) | 2019-06-06 |
| JP6931229B2 JP6931229B2 (ja) | 2021-09-01 |
Family
ID=56008588
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552966A Active JP6931229B2 (ja) | 2015-04-30 | 2016-04-29 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2018041788A Active JP6928380B2 (ja) | 2015-04-30 | 2018-03-08 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2021129196A Active JP7162929B2 (ja) | 2015-04-30 | 2021-08-05 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018041788A Active JP6928380B2 (ja) | 2015-04-30 | 2018-03-08 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
| JP2021129196A Active JP7162929B2 (ja) | 2015-04-30 | 2021-08-05 | Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス |
Country Status (31)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015030881A2 (pt) | 2013-06-14 | 2017-10-24 | Psioxus Theraupeutics Ltd | regime de dosagem e formulações para adenovírus de tipo b |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| NO3021859T3 (cg-RX-API-DMAC7.html) | 2013-10-25 | 2018-04-28 | ||
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| EA037611B1 (ru) | 2015-04-30 | 2021-04-21 | Псайоксус Терапьютикс Лимитед | Онколитический аденовирус, кодирующий белок b7 |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| WO2017103291A1 (en) * | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| EP4190906B1 (en) * | 2016-03-31 | 2025-08-20 | The European Molecular Biology Laboratory | Engineered polypeptides derived from adenoviral fibre protein and vlps containing the polypeptides |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
| ES2981703T3 (es) | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| MX2019003546A (es) * | 2016-09-27 | 2019-09-19 | Sator Therapeutics LLC | Virus oncoliticos optimizados y usos de los mismos. |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| CN110520438A (zh) | 2017-02-03 | 2019-11-29 | 匹兹堡大学联邦系统高等教育 | 溶瘤病毒疗法 |
| EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
| WO2018218151A1 (en) * | 2017-05-25 | 2018-11-29 | University Of Central Florida Research Foundation, Inc. | Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells |
| US11253608B2 (en) | 2017-05-26 | 2022-02-22 | Epicentrx, Inc. | Recombinant adenoviruses carrying transgenes |
| JP7394628B2 (ja) | 2017-06-01 | 2023-12-08 | アカミス バイオ リミテッド | 腫瘍溶解性ウイルスおよび方法 |
| WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| WO2019173334A1 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| CN111989397A (zh) * | 2018-03-30 | 2020-11-24 | 藤堂具纪 | 肿胀发生抑制型溶瘤病毒 |
| JP2022502074A (ja) * | 2018-09-10 | 2022-01-11 | ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド | 改変された腫瘍溶解性ウイルス、組成物、およびその使用 |
| BR112021017551A2 (pt) * | 2019-03-05 | 2021-11-09 | Amgen Inc | Uso de vírus oncolíticos para o tratamento de câncer |
| EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| WO2020230838A1 (ja) * | 2019-05-14 | 2020-11-19 | オンコリスバイオファーマ株式会社 | 腫瘍組織に腫瘍溶解ウイルスを投与する方法、及び投与用デバイス |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| JP7697147B2 (ja) * | 2021-06-03 | 2025-06-23 | 上▲海▼允英生物医▲薬▼科技有限公司 | 腫瘍溶解性ウイルスベクターおよびその適用 |
| WO2023049852A1 (en) | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| WO2023180527A1 (en) * | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| CZ287157B6 (en) | 1993-07-13 | 2000-10-11 | Rhone Poulenc Rorer Sa | Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| US6420524B1 (en) | 1997-02-20 | 2002-07-16 | Johns Hopkins University School Of Medicine | Gain of function mutations in ATP-dependent transposition proteins |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| WO2000015823A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
| CA2354024C (en) * | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| DK1550722T3 (da) | 1999-05-17 | 2007-10-08 | Crucell Holland Bv | Rekombinant human adenovirus serotype 35 |
| AU5464000A (en) | 1999-06-01 | 2000-12-18 | University Of Washington | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| ES2254359T3 (es) * | 2000-01-21 | 2006-06-16 | Biovex Limited | Cepa viral para el tratamiento oncolitico de canceres. |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| AU2001265154A1 (en) | 2000-05-31 | 2001-12-11 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| EP1348030B1 (en) | 2001-01-04 | 2009-11-25 | Wadell, Göran | Viral vector for gene therapy |
| US20050175589A1 (en) * | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| EP1470233A1 (en) | 2002-02-01 | 2004-10-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| CN1705740B (zh) * | 2002-10-15 | 2013-07-24 | 佩尔·松内·霍尔姆 | 具有反向基因表达的腺病毒及其应用 |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| WO2005010149A2 (en) | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| DE602005025340D1 (de) | 2004-05-26 | 2011-01-27 | Bayer Schering Pharma Ag | Chimäre adenoviren zur verwendung in der krebsbehandlung |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | 细胞基因系统有限公司 | 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体 |
| JP2008511336A (ja) * | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法 |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| WO2009143610A1 (en) | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CN101381742A (zh) * | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| WO2011043719A1 (en) * | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| WO2012024351A2 (en) | 2010-08-16 | 2012-02-23 | Salk Institute For Biological Studies | Adenoviral assembly method |
| CA2812096A1 (en) * | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Adenoviral vectors and methods and uses related thereto |
| CA2812093A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| EP2780020A4 (en) | 2011-11-14 | 2016-03-02 | Regenerative Sciences Llc | SUSPENDED PARTICLE DISTRIBUTION SYSTEMS AND METHODS |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| CN105407902A (zh) | 2013-03-05 | 2016-03-16 | 贝勒医学院 | 溶瘤病毒 |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| NO3021859T3 (cg-RX-API-DMAC7.html) * | 2013-10-25 | 2018-04-28 | ||
| AU2014352749A1 (en) | 2013-11-22 | 2016-06-09 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| US11485791B2 (en) | 2015-03-17 | 2022-11-01 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies |
| EA037611B1 (ru) | 2015-04-30 | 2021-04-21 | Псайоксус Терапьютикс Лимитед | Онколитический аденовирус, кодирующий белок b7 |
| WO2017103291A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| WO2017161360A2 (en) | 2016-03-18 | 2017-09-21 | Nant Holdings Ip, Llc | Multimodal vector for dendritic cell infection |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
| EP3529361B1 (en) | 2016-10-20 | 2021-03-24 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| JP7394628B2 (ja) * | 2017-06-01 | 2023-12-08 | アカミス バイオ リミテッド | 腫瘍溶解性ウイルスおよび方法 |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 KR KR1020257028976A patent/KR20250134212A/ko active Pending
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 SM SM20200222T patent/SMT202000222T1/it unknown
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en not_active Ceased
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 KR KR1020247006825A patent/KR102854512B1/ko active Active
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko not_active Withdrawn
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active Active
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514199A5 (cg-RX-API-DMAC7.html) | ||
| Conlon et al. | Cytokines in the treatment of cancer | |
| Cao et al. | Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance | |
| Sharma et al. | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | |
| CN105307671B (zh) | 增强过继细胞疗法 | |
| US20220162279A1 (en) | Combination immunotherapy | |
| Homey et al. | Chemokines: agents for the immunotherapy of cancer? | |
| JP2018139586A5 (cg-RX-API-DMAC7.html) | ||
| JP2024096876A (ja) | 一本鎖および多鎖キメラポリペプチドならびにその使用方法 | |
| Sandau et al. | IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool | |
| TWI850282B (zh) | 用於治療癌症之質體建構體和使用方法 | |
| HRP20200439T1 (hr) | Onkolitički adenovirus koji kodira protein b7 | |
| JP2017006118A (ja) | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 | |
| AU2018277294A1 (en) | Oncolytic virus and method | |
| US20220125951A1 (en) | Microenvironment sensors to regulate engineered gene expression | |
| Cervera-Carrascon et al. | Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. | |
| WO2021259206A1 (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
| Liang et al. | Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity | |
| JP2022542461A (ja) | 免疫回避腫瘍の処置 | |
| CN116322785A (zh) | 包含il-10的双细胞因子融合蛋白 | |
| JP2023521409A (ja) | インビボ遺伝子治療のための前処理レジメン | |
| Rossari et al. | Gene-based delivery of immune-activating cytokines for cancer treatment | |
| Cirella et al. | Interleukin-18 in cancer immunology and immunotherapy | |
| Zhang et al. | Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma | |
| Lo et al. | Differential antitumor effect of interleukin‐12 family cytokines on orthotopic hepatocellular carcinoma |